CLDX Q4 2023 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+156.1% YoY

Gross Profit

-$26M-636.5% margin

Operating Income

-$48M-1152.9% margin

Net Income

-$43M-1048.3% margin

EPS (Diluted)

$-0.83

QoQ Revenue Growth

+172.3%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$33M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$466M

Total Liabilities

$36M

Stockholders' Equity

$429M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$2M	+156.1%
Gross Profit	-$26M	-$21M	-23.5%
Operating Income	-$48M	-$28M	-70.8%
Net Income	-$43M	-$26M	-63.5%

Revenue Segments

Grant

$5M95%

Service

$262,0005%